| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V Dariy, K Serikov, O Kmyta, T Rybalko, O Kolesny. PERSONIFICATION OF ANTIHYPERTENSIVE THERAPY IN ISCHEMIC CEREBRAL STROKE. Georgian medical news. issue 349. 2024-07-04. PMID:38963206. |
for the purpose of antihypertensive correction of the hyperkinetic type of arterial hypertension (ci ≥ 3,80 l×min-1×m-2), a solution of magnesium sulfate was used intravenously at a dose of 2500-5000 mg×day-1 in combination with bisoprolol 5-10 mg×day-1 orally. |
2024-07-04 |
2024-07-10 |
Not clear |
| Minghui Dong, Dandan Sun, Jing Li, Yuzhu Zhang, Xingyu Fang, Mingyang Liu, Chang Su, Mingyan Ding, Fang Zh. Comprehensive Evaluation of Cancer Treatment-Related Cardiac Dysfunction by Ultrasound Myocardial Strain: A Network Meta-Analysis. Cardiology in review. 2023-10-17. PMID:37847047. |
interestingly, cardioprotective treatment regimens, such as anthracycline plus bisoprolol plus angiotensin-converting enzyme inhibitors (ant+bb+aceis) (wmd -2.79; 95% ci, -5.06 to -0.52), and ant plus rosuvastatin (statins) (wmd -2.92; 95% ci, -5.54 to -0.29), were more likely to improve gls than ant at t12. |
2023-10-17 |
2023-11-08 |
human |
| Lovisa Ekestubbe, Gary Alan Bass, Maximilian Peter Forssten, Gabriel Sjölin, Yang Cao, Peter Matthiessen, Rebecka Ahl Hulme, Shahin Mohsen. Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery. Scientific reports. vol 12. issue 1. 2022-03-29. PMID:35347168. |
irr (95% ci): 1.45 (0.89-2.37), p = 0.132], bisoprolol [adj. |
2022-03-29 |
2023-08-13 |
Not clear |
| Yohei Kawano, Masashi Nagata, Saeko Nakamura, Yuuki Akagi, Tatsunori Suzuki, Emi Tsukada, Mai Hoshiko, Azusa Kujirai, Satoshi Nakamatsu, Tomoki Nishikawa, Aya Enomoto, Kenichi Negishi, Shuji Shimada, Takao Aoyama, Yasunari Man. Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users. Biological & pharmaceutical bulletin. vol 44. issue 5. 2021-11-22. PMID:33952817. |
several antihypertensive drugs, such as amlodipine and bisoprolol, were associated with a decreased risk of bleeding (warfarin + amlodipine [aor, 0.64; 95% confidence interval (ci): 0.41-0.98], doacs + bisoprolol [aor, 0.51; 95% ci, 0.33-0.80]). |
2021-11-22 |
2023-08-13 |
Not clear |
| Kuo-Yang Huang, Ping-Tao Tseng, Yi-Cheng Wu, Yu-Kang Tu, Brendon Stubbs, Kuan-Pin Su, Yutaka J Matsuoka, Chih-Wei Hsu, Ching-Hsiung Lin, Yen-Wen Chen, Pao-Yen Li. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Scientific reports. vol 11. issue 1. 2021-08-26. PMID:33432057. |
overall nma revealed that only oral timolol [risk ratio (rr) = 3.35 (95% confidence interval (ci) 1.04-10.85)] and infusion of propranolol [rr = 10.19 (95% ci 1.29-80.41)] were associated with significantly higher incidences of asthma attack than the placebo, whereas oral celiprolol [rr = 0.39 (95% ci 0.04-4.11)], oral celiprolol and propranolol [rr = 0.46 (95% ci 0.02-11.65)], oral bisoprolol [rr = 0.46 (95% ci 0.02-11.65)], oral atenolol [rr = 0.51 (95% ci 0.20-1.28)], infusion of practolol [rr = 0.80 (95% ci 0.03-25.14)], and infusion of sotalol [rr = 0.91 (95% ci 0.08-10.65)] were associated with relatively lower incidences of asthma attack than the placebo. |
2021-08-26 |
2023-08-13 |
human |
| Xiaoming Xu, Yang Yang, Gendong Zhou, Zhengxuan Du, Xiaohong Zhang, Wei Mao, Hongwen Ca. Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM. vol 2021. 2021-08-20. PMID:34408783. |
the results showed that, compared with western medicine alone, the combination of qili qingxin capsule and western medicine treatment has better efficacy (metoprolol: rr: 1.24, 95%ci 1.14-1.34; carvedilol: rr: 1.24, 95%ci 1.14-1.34; trimetazidine: rr: 1.20, 95%ci: 1.12-1.27; sacubitril valsartan sodium: rr: 1.23, 95%ci: 1.11-1.36; sodium nitroprusside: rr: 1.33, 95%ci: 1.23-1.45; and bisoprolol: rr: 1.31, 95%ci: 1.15-1.49) and increased the level of lvef, lvedd, and 6mwt of patients with chf and reduced the adverse effects and the level of hr, lvesd, bnp, and hs-ctnt as well. |
2021-08-20 |
2023-08-13 |
Not clear |
| Seung Jin Jun, Kyung Hwan Kim, Myung Ho Jeong, Min Chul Kim, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Myeong Chan Cho, Jei Keon Chae, Hun Sik Park, Jong Sun Park, Young Keun Ah. Effects of Bisoprolol Are Comparable with Carvedilol in Secondary Prevention of Acute Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention. Chonnam medical journal. vol 54. issue 2. 2020-10-01. PMID:29854677. |
in the subgroup analysis, the cumulative incidence of maces was lower in the bisoprolol group in patients having a killip class of iii or iv than in the carvedilol group (hr=0.512, 95% ci: 0.263-0.998, p=0.049). |
2020-10-01 |
2023-08-13 |
Not clear |
| M Sabidó, Hohenberger Thilo, Grassi Guid. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. Pharmacological research. vol 139. 2019-05-13. PMID:30408572. |
the hr of bisoprolol versus other β-blockers for angina was 0.58 (95% ci: 0.50-0.68) and versus drugs other than β-blockers was 0.77 (95% ci: 0.68-0.88), respectively. |
2019-05-13 |
2023-08-13 |
Not clear |
| M Sabidó, Hohenberger Thilo, Grassi Guid. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. Pharmacological research. vol 139. 2019-05-13. PMID:30408572. |
at 5 years, the hr of bisoprolol versus other β-blockers, and drugs other than β-blockers, for arrhythmia was 0.60 (95% ci: 0.35-1.0) and 0.61 (95% ci: 0.40-0.93), respectively. |
2019-05-13 |
2023-08-13 |
Not clear |
| M Sabidó, Hohenberger Thilo, Grassi Guid. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. Pharmacological research. vol 139. 2019-05-13. PMID:30408572. |
over the total follow-up (≤14 years), the hr of bisoprolol versus other β-blockers and drugs other than β-blockers for mortality was 0.45 (95% ci: 0.34-0.61) and 0.50 (95% ci: 0.38-0.66), respectively. |
2019-05-13 |
2023-08-13 |
Not clear |
| M Sabidó, Hohenberger Thilo, Grassi Guid. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. Pharmacological research. vol 139. 2019-05-13. PMID:30408572. |
for myocardial infarction, the hr of bisoprolol versus drugs other than β-blockers up to 14 years was 0.34 (95% ci: 0.23-0.52) and versus other β-blockers up to 5 years was 0.45 (95% ci: 0.27-0.75). |
2019-05-13 |
2023-08-13 |
Not clear |
| Meritxell Sabidó, Thilo Hohenberger, Guido Grass. Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness. Pharmacological research. vol 130. 2019-01-18. PMID:29366925. |
patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (hr for <15 years 0.34; 95% ci 0.18-0.67) versus other β-blockers, and from 5 to <15 years (hr for <15 years 0.52; 95% ci 0.27-1.00) versus drugs other than β-blockers. |
2019-01-18 |
2023-08-13 |
Not clear |
| Tianlun Yang, Yinong Jiang, Yuming Hao, Shuxian Zhou, Xinjuan Xu, Baiming Qu, Xue Lin, Tianrong M. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertension research : official journal of the Japanese Society of Hypertension. vol 40. issue 1. 2017-08-10. PMID:27534738. |
furthermore, in the last 4 h of the treatment period, bisoprolol demonstrated non-inferiority vs. metoprolol cr/zok in lowering the mean dynamic dbp (lsmeans of difference: -1.00; 97.5% ci: -4.79, 2.78; p=0.5495). |
2017-08-10 |
2023-08-13 |
Not clear |
| Ting-Tse Lin, K Arnold Chan, Ho-Min Chen, Chao-Lun Lai, Mei-Shu La. Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database. Scientific reports. vol 5. 2016-09-12. PMID:26328923. |
after accounting for baseline differences, patients treated with bisoprolol (hr 0.87, 95% ci 0.72-1.05, p = 0.14) or propranolol (hr 1.07, 95% ci 0.84-1.36, p = 0.58) had a similar risk of all-cause death in comparison with carvedilol. |
2016-09-12 |
2023-08-13 |
Not clear |
| Vincent Yi-Fong Su, Yu-Sheng Chang, Yu-Wen Hu, Man-Hsin Hung, Shuo-Ming Ou, Fa-Yauh Lee, Kun-Ta Chou, Kuang-Yao Yang, Diahn-Warng Perng, Tzeng-Ji Chen, Chia-Jen Li. Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. Medicine. vol 95. issue 5. 2016-06-14. PMID:26844454. |
after adjustment for age, sex, comorbidities, and severity of hf and copd, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (hr) = 0.76, 95% confidence interval (ci) = 0.59-0.97, p = 0.030; high dose: adjusted hr = 0.40, 95% ci = 0.26-0.63, p < 0.001] compared with nonusers, whereas no survival difference was observed for carvedilol or metoprolol. |
2016-06-14 |
2023-08-13 |
human |
| Darius Lucian Lazarus, Cynthia Anne Jackevicius, Hassan Behlouli, Helen Johansen, Louise Pilot. Population-based analysis of class effect of β blockers in heart failure. The American journal of cardiology. vol 107. issue 8. 2011-06-07. PMID:21349489. |
after controlling for several different covariates, we found that carvedilol (hazard ratio [hr] 1.04, 95% confidence interval [ci] 0.97 to 1.12, p = 0.22) and bisoprolol (hr 0.96, 95% ci 0.91 to 1.01, p = 0.16) were not superior to metoprolol in improving survival. |
2011-06-07 |
2023-08-12 |
Not clear |
| Felix van Lier, Olaf Schouten, Sanne E Hoeks, Louis van de Ven, Robert Jan Stolker, Jeroen J Bax, Don Polderman. Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery. The American journal of cardiology. vol 105. issue 1. 2010-03-04. PMID:20102888. |
no association with bisoprolol therapy was found (or 1.16, 95% ci 0.4 to 3.4). |
2010-03-04 |
2023-08-12 |
Not clear |
| K Schnellbacher, H P Bestehorn, H Roskam. Hemodynamics and exercise tolerance after bisoprolol, nifedipine, and their combination in patients with angina pectoris. Journal of cardiovascular pharmacology. vol 16 Suppl 5. 2001-09-27. PMID:11527130. |
twenty-one male patients aged between 41 and 68 years and suffering from chronic stable angina pectoris and coronary artery disease confirmed by angiography took part in a randomized, double-blind study to examine the acute effect of 10 mg of bisoprolol, 20 mg of nifedipine, and a combination of the two drugs on hemodynamics at rest and during exercise [heart rate (hr), systolic blood pressure (sbp), rate-pressure product (rpp), cardiac index (ci), total peripheral resistance (tpr), and pulmonary capillary wedge pressure (pcp)], the behavior of the st segment (st), and exercise tolerance until occurrence of an st-segment depression of 0.1 mv (w-st01) and until onset of anginal pain (w-ap1). |
2001-09-27 |
2023-08-12 |
Not clear |
| K Schnellbacher, H P Bestehorn, H Roskam. Hemodynamics and exercise tolerance after bisoprolol, nifedipine, and their combination in patients with angina pectoris. Journal of cardiovascular pharmacology. vol 16 Suppl 5. 2001-09-27. PMID:11527130. |
on exercise, bisoprolol resulted in significant changes in hr (-16%), rpp (-22%), and ci (-16%), as well as in tpr (+ 13%); pcp was not significantly affected. |
2001-09-27 |
2023-08-12 |
Not clear |
| P Jamin, F LeCoz, C Funck-Brentano, J M Poirier, P Jaillo. Relationships between acute and chronic beta-blocking effects of bisoprolol in healthy volunteers: a practical approach to predict intensity of beta-blockade. Journal of cardiovascular pharmacology. vol 23. issue 4. 1994-07-08. PMID:7516019. |
after repeated bisoprolol administration, steady-state plasma levels were achieved and 88% of the observed decreases in exercise hr were within the 95% confidence interval (ci) for individual prediction. |
1994-07-08 |
2023-08-12 |
human |